Emcure Pharmaceuticals signs agreement with Gilead Sciences Ireland UC

03 Oct 2024 Evaluate

Emcure Pharmaceuticals has signed a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries.

Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare.

Emcure’s commitment to affordability and quality is backed by its expertise in manufacturing complex generic drugs. This partnership highlights Emcure's role as a leading manufacturer of generic pharma products and its commitment to innovative and affordable healthcare globally.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.


Emcure Pharma Share Price

1368.55 -20.55 (-1.48%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.